Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | FAAH | O00519 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990812 | 0.84 | RAB9A (0.55) | CHRNA7GRM5LMNASMN1; SMN2TSHR | |
| SCHEMBL990236 | 0.82 | GRM5 (0.43) | GRM5CNR1 | |
| SCHEMBL992116 | 0.82 | GRM5 (0.43) | GRM5CNR1 | |
| SCHEMBL990340 | 0.80 | L3MBTL1 (0.59) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL992162 | 0.80 | GRM5 (0.56) | GRM5 | |
| SCHEMBL990196 | 0.80 | CNR2 (0.48) | GRM5L3MBTL1NPC1RAB9A | |
| SCHEMBL991006 | 0.80 | GRM5 (0.46) | GRM5L3MBTL1TSHRNPC1RAB9A | |
| SCHEMBL992693 | 0.80 | GRM5 (0.46) | GRM5L3MBTL1TSHRNPC1RAB9A | |
| SCHEMBL990845 | 0.80 | GRM5 (0.56) | GRM5 | |
| SCHEMBL992298 | 0.80 | CNR2 (0.48) | GRM5L3MBTL1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011137206-A1 | PREDICTIVE MARKERS USEFUL IN THE TREATMENT OF FRAGILE X SYNDROME (FXS) | NOVARTIS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
| EP-2320892-A2 | COMBINATION PRODUCTS | Novartis AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |